The diverse effects of ketamine, jack-of-all-trades: a narrative review.

British journal of anaesthesia  – March 01, 2025

Source: PubMed

Summary

Beyond its well-known role in anaesthesia, ketamine emerges as a remarkably versatile medicine. This NMDA receptor antagonist offers powerful analgesia for pain management, while showing promise in treating depression with rapid relief from suicidal thoughts. Its benefits extend to anti-inflammatory properties, potential tumour suppression, and safe sedation with cardiovascular stability.

Abstract

Ketamine, an N-methyl-D-aspartic acid receptor antagonist that was first discovered in 1962, has become established in anaesthesia providing dose-dependent anaesthetic, sedative, and analgesic effects. Ketamine, however, also acts on a wide range of other cellular targets, resulting in interesting and diverse effects on both physiological and pathological processes. Potential beneficial properties of ketamine include cardiovascular stability for patients undergoing sedation or anaesthesia, analgesia in both acute and chronic pain, bronchodilation in severe refractory asthma, anti-inflammatory properties particularly in sepsis, tumour inhibition, and antidepressant properties with marked ability to reverse suicidal ideation. The reluctance to adopt ketamine into routine practice is likely attributable in part to the stigma and negative reputation associated with its perceived side-effects and potential for abuse. This review explores the diverse properties and therapeutic potentials of ketamine being investigated across different fields whilst also identifying areas for ongoing and future research. Given the diverse range of potential benefits and promising early work, ketamine should be the focus of ongoing research in multiple different specialty areas. This includes areas relevant to anaesthesia and perioperative medicine, such as acute and chronic pain management, ICU sedation, and even tumour suppression in those undergoing surgical resection of malignancies.

Comments

No comments yet.

Log in to comment